Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
In: Blood, Jg. 140 (2022-11-15), S. 7047-7049
Online
unknown
Zugriff:
Titel: |
Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
|
---|---|
Autor/in / Beteiligte Person: | Ghosh, Nilanjan ; Sharman, Jeff P. ; Barrientos, Jacqueline C. ; Brander, Danielle ; Gutierrez, Meghan ; Wu, Linda ; Qureshi, Zaina P. ; Upasani, Sandhya ; Naganuma, Maoko ; Mato, Anthony R. |
Link: | |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), S. 7047-7049 |
Veröffentlichung: | American Society of Hematology, 2022 |
Medientyp: | unknown |
ISSN: | 1528-0020 (print) ; 0006-4971 (print) |
DOI: | 10.1182/blood-2022-155649 |
Schlagwort: |
|
Sonstiges: |
|